Prospective cohort study of Suture-Line recurrence and clinical outcomes in stage 1A Non-Small cell lung cancer

Lung Cancer, Год журнала: 2025, Номер 202, С. 108465 - 108465

Опубликована: Март 1, 2025

Язык: Английский

---

Reducing pERKs to Break “RAS”istance to Sotorasib

Journal of Thoracic Oncology, Год журнала: 2025, Номер 20(3), С. 259 - 261

Опубликована: Март 1, 2025

Язык: Английский

---

Efficacy of Tislelizumab in Lung Cancer Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus, Год журнала: 2025, Номер unknown

Опубликована: Март 15, 2025

This systematic review and meta-analysis evaluated the efficacy of tislelizumab, alone or in combination with chemotherapy, patients lung cancer. A comprehensive literature search was conducted across PubMed, Embase, Web Science, CENTRAL databases until February 15, 2025. Only randomized controlled trials (RCTs) comparing tislelizumab control treatments cancer were included. The primary outcomes assessed overall survival (OS) progression-free (PFS). Four phase-III RCTs involving 1,837 included analysis. results demonstrated that significantly improved OS (hazard ratios (HR): 0.72, 95% CI: 0.63-0.81) PFS (HR: 0.61, 0.54-0.68) compared to treatments. Subgroup analyses revealed consistent benefits both non-small-cell (NSCLC) small-cell (SCLC) populations, no significant differences between types. Similarly, comparable whether administered as monotherapy chemotherapy. Low heterogeneity observed among studies, suggesting consistency treatment effects. Follow-up duration studies ranged from 14.2 16.7 months. These findings indicate either combined is an effective option for patients, demonstrating improvements outcomes. However, further high-quality are needed validate these results, particularly SCLC where evidence limited a single study. Future research should also consider patient-specific factors such age, gender, comorbidities refine strategies.

Язык: Английский

---

Multi-omics pan-cancer analysis reveals the diagnostic and prognostic value of C8orf76, with experimental validation of its impact on lung adenocarcinoma cell proliferation

Frontiers in Genetics, Год журнала: 2025, Номер 16

Опубликована: Март 26, 2025

Background Chromosome 8 open reading frame 76 (C8orf76) is a nuclear protein-encoding gene, has received limited attention in current study. Multi-omics pan-cancer analysis focused on the diagnosis, prognosis, immune cell infiltration, methylation, and anti-cancer drug sensitivity remains an enigma. The effect of C8orf76 lung adenocarcinoma (LUAD) unknown. Methods by utilizing datasets including UALCAN, TIMER 2.0, Human Protein Atlas (HPA), Cancer Genome (TCGA), Genotype-Tissue Expression (GTEx), cBioPortal, Gene Profiling Interactive Analysis (GEPIA), OncoDB, MethSurv datasets, were conducted to analyze across 33 cancer types. Furthermore, differential R packages uesd for in-depth C8orf76. correlation between expression diagnostic, genetic alteration, mRNA modification, DNA lncRNA-miRNA-C8orf76 regulatory network, anti-tumor drugs response explored evaluate potential roles Most importantly, experiments quantitative polymerase chain reaction (qPCR), RNA interference (RNAi), Western blotting (WB), Edu staining, performed experimental verification. Results It was noted that markedly elevated multiple tumor Moreover, showed as diagnostic prognostic biomarker. Besides, it confirmed related infiltration cells. network established study LUAD. Experimental validation LUAD A549 cells demonstrated knockdown significantly inhibited proliferation Conclusion present first report multi-omics predicts promising target immunology, chemotherapy, highlighting its influence with validation.

Язык: Английский

---

Identification and validation of crotonylation-related diagnostic markers for lung adenocarcinoma via weighted correlation network analysis and machine learning

Translational Lung Cancer Research, Год журнала: 2025, Номер 14(3), С. 940 - 962

Опубликована: Март 1, 2025

Lung adenocarcinoma (LUAD) is one of the most common tumors in terms incidence and mortality worldwide. Posttranslational modifications, including crotonylation, play a crucial role various biological processes diseases. However, crotonylation LUAD remains unclear. Our research focuses on identifying key genes that are linked to prognosis. We also aim clarify their microenvironment advance clinical translation related targets. used RNA-sequencing data from The Cancer Genome Atlas (TCGA) Genotype-Tissue Expression (GTEx) database identify differentially expressed (DEGs) LUAD. Weighted correlation network analysis (WGCNA) was applied construct gene networks, hub were identified using protein-protein interaction (PPI) analysis. prognostic value assessed Kaplan-Meier plots, with immune infiltration analyzed via Tumor Immune Estimation Resource (TIMER) other algorithms. then verified these through samples confirmed MMACHC GAPDH, SLC25A13, MMACHC, HDAC1 as potential crotonylation-related biomarkers for These found be overexpressed associated poor They showed significant correlations cell immune-inflammatory pathways. Functional experiments knockdown inhibited proliferation migration, induced apoptosis, enhanced efficacy immunotherapy study suggests genes, particularly may serve novel therapeutic targets diagnostic markers

Язык: Английский

---

Ginsenoside Rk1 inhibits the malignant progression of lung cancer by inactivating the INSR/PI3K/AKT pathway

Tissue and Cell, Год журнала: 2025, Номер unknown, С. 102880 - 102880

Опубликована: Март 1, 2025

Язык: Английский

---

Artificial Intelligence in Clinical Trials of Lung Cancer: Current and Future Prospects

Опубликована: Дек. 5, 2024

Язык: Английский

---